<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02087644</url>
  </required_header>
  <id_info>
    <org_study_id>CYT003-QbG10 13</org_study_id>
    <nct_id>NCT02087644</nct_id>
  </id_info>
  <brief_title>CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Phase IIb Study of CYT003-QbG10 (CYT003), a TLR9 Agonist, in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild
      to moderate allergic asthma not sufficiently controlled on inhaled steroid.

      Altogether 170 patients, randomized to two treatment groups will be included. Key outcome
      measures are patient reported parameters on their asthma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase IIb study in patients to evaluate CYT003- QbG10 versus placebo, in patients with mild
      to moderate allergic asthma not sufficiently controlled on inhaled steroid.

      Altogether 170 patients, randomized to two treatment groups will be included. Key outcome
      measures are patient reported parameters on their asthma at the time of primary endpoint and
      throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CYT003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injections of CYT003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injections of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT003</intervention_name>
    <description>Injections</description>
    <arm_group_label>CYT003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injections</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent.

          2. Complete all protocol requirements.

          3. Between 18 to 65 years of age.

          4. Persistent allergic asthma patients

          5. Forced expiratory volume in one second (FEV1) ≥60% to ≤ 90% of predicted value

          6. Reversibility of airway obstruction

          7. Patients meeting the contraception requirements

          8. At baseline: Patients treated with ICS and insufficiently controlled

          9. Blood eosinophil count above a certain level

        Exclusion Criteria:

          1. Failure to meet at least 80% compliance of use of the patient e-diary/ peak expiratory
             flow (PEF) meter (AM3 device) at the baseline visit

          2. Treatment or hospitalization for asthma exacerbation within past 2 months

          3. Current use or use of systemic corticosteroids within past 2 months

          4. Current smokers.

          5. Ex-smokers for less than 1 year, with a tobacco smoking history of &gt;10 pack years

          6. Major surgery within 3 months prior to signing the ICF or anticipated during study

          7. Presence or history of clinically relevant cardiovascular, renal, pulmonary (e.g.
             COPD), endocrine, autoimmune, dermatological, neurological, psychiatric, or ocular
             disease as judged by the investigator.

          8. Any malignancy within the previous 5 years

          9. Presence of suspicious lymphadenopathy or splenomegaly on physical examination.

         10. Confirmed or suspected current infection with human immunodeficiency virus (HIV),
             hepatitis B virus (HBV), or hepatitis C virus (HCV).

         11. Presence of active infectious disease as judged by the investigator

         12. Active autoimmune diseases or prior diagnosis of autoimmune disease including but not
             limited to rheumatoid arthritis, lupus and ulcerative colitis.

         13. Pregnancy (based on positive urine test at screening visit) or lactation.

         14. Female planning to become pregnant during the study period.

         15. Patients with any history of abuse of alcohol or other recreational drugs.

         16. Ongoing or planned specific immunotherapy (SIT) during the whole study period or SIT
             completed within the last 3 years.

         17. BMI &gt;40

         18. Use of investigational or approved biologics/immune-modulators within the last 6
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Casale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-4799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

